Delirium is defined as a transient, usually reversible, cause of mental dysfunction and manifests with a wide range of neuropsychiatric abnormalities. It happens when an individual has sudden confusion or a sudden change in mental status. Delirium often clears in a few days or weeks. Some may not respond to treatment for many weeks. Early recognition and on-time treatment can help to reduce morbidity, mortality, health care costs, and length of hospital stay.
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/4430
Delirium can be caused due to various factors such as alcohol abuse, exposure to certain drugs, old age, surgery or other medical procedures and factors such as diet, physical trauma, exposure to infectious or toxic agents, and other occupational and behavioral factors. There are two types of delirium, such as hypoactive delirium and hyperactive delirium. Patients become overactive (agitation in delirium) in hyperactive delirium. Thus, there is an increasing demand for new medicines for the management of agitation in delirium.
Major players operating in the global agitation in delirium management market are BioXcel Therapeutics, Inc., Pfizer, Inc., Zydus Cadila, Akorn Incorporated, Novartis International AG, Fresenius Kabi AG, Mylan N.V., Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Key Market Drivers:
Increasing prevalence of delirium coupled with the growing geriatric population worldwide is expected to propel growth of the agitation in delirium management market during the forecast period. One-third of general medical patients who are 70 years of age or older have delirium. For instance, according to the World Health Organization (WHO), by 2030, one in six people in the world will be aged 60 years or over, and by 2050, the world’s population of people aged 60 years and older will double (2.1 billion), while the number of people aged 80 years or older is expected to reach 426 million, between 2020 and 2050.
Moreover, the emergence of COVID-19 is expected to augment the growth of the agitation in delirium management market. Patients with severe COVID-19 are highly at risk of developing cognitive impairment, including depression and delirium. For instance, in February 2021, BioXcel Therapeutics started Phase II PLACIDITY clinical trial of BXCL501 in patients with delirium related agitation. The trial includes patients who experience agitation in the intensive care unit (ICU) associated with and without COVID-19.
COVID-19 Impact Analysis:
The pandemic is expected to boost the growth of the market. Patients with severe COVID-19 infection are highly at risk of developing cognitive impairment, including delirium, both during the treatment and after it. Moreover, symptoms like fever and increased invasive mechanical ventilation during COVID-19 increases the risks of delirium. Thus, market players are focusing on developing the treatment for delirium occurring in people in COVID-19. According to the WHO, as of 11:39am CEST, 4 October 2021, there have been 234,609,003 confirmed cases of COVID-19, including 4,797,368 deaths worldwide.
The agitation in delirium management market is expected to exhibit a CAGR of XX % during the forecast period owing to increase in research activities for the development of safe and effective treatment or drug for the treatment of agitation in delirium. For instance, in April 2019, Royal Philips launched VitalMinds, new non-pharmacological approach to help reduce delirium in the ICU, following CE Mark, and is available in Austria, Germany, Finland, Switzerland, and Sweden.
Among regions, North America is expected to witness significant growth in the agitation in delirium management market due to the increasing prevalence of delirium and growing aging population in this region. For instance, according to the American Delirium Society, each year, more than 7 million people in the United States suffer from delirium. Delirium is a state of confusion that comes on very suddenly and lasts hours to days.
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/4430
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027